Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS2 | Q07890 | 1/20 | 0.57 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.50 |
| ▸ | ITGAL | P20701 | 2/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24042700 | 1.00 | SOS2 (0.57) | SOS2ITGB2ICAM1ITGALBRPF1 | |
| SCHEMBL24975589 | 1.00 | SOS2 (0.57) | SOS2ITGB2ICAM1ITGALBRPF1 | |
| SCHEMBL27429060 | 0.90 | ITGB2 (0.59) | SOS2ITGB2ICAM1ITGALBRPF1 | |
| SCHEMBL30955892 | 0.90 | ITGB2 (0.59) | SOS2ITGB2ICAM1ITGALBRPF1 | |
| SCHEMBL21392024 | 0.90 | ITGB2 (0.59) | SOS2ITGB2ICAM1ITGALBRPF1 | |
| SCHEMBL28516953 | 0.82 | ITGB2 (0.63) | SOS2ITGB2ICAM1ITGALBRPF1 | |
| SCHEMBL28516957 | 0.82 | ITGB2 (0.63) | SOS2ITGB2ICAM1ITGALBRPF1 | |
| SCHEMBL22989842 | 0.81 | SOS2 (0.51) | SOS2ITGB2ICAM1ITGALNR3C1 | |
| SCHEMBL10068458 | 0.81 | SOS2 (0.68) | SOS2ITGB2ICAM1ITGALBRPF1 | |
| SCHEMBL27431642 | 0.81 | ITGB2 (0.58) | SOS2ITGB2ICAM1ITGALBRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230119612-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3052121-B1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | UNIV LELAND STANFORD JUNIOR (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-20220133893-A1 | Therapeutic Nanomaterials | UNIVERSITY OF CONNECTICUT | 2022-05-05 | — | — | US | disclosed |
| WO-2022081721-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220000968-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMAN-LA ROCHE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11008366-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2015051122-A2 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8987414-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMANN-LA ROCHE, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8927500-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140378390-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8859723-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210743-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | SOS2 1976/4885ITGB2 4698/4885ICAM1 3533/4885 |
| US-20130210743-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | SOS2 2968/4885ITGB2 4513/4885ICAM1 2436/4885 |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | SOS2 3108/4885ITGB2 3009/4885ICAM1 1904/4885 |
| US-20220133893-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | SOS2 2074/4885ITGB2 2466/4885ICAM1 99/4885 |
| US-20230119612-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | SOS2 2246/4885ITGB2 4628/4885ICAM1 2383/4885 |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | ILK, EPCAM, MMP8 | SOS2 1473/4885ITGB2 53/4885ICAM1 5/4885 |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | SOS2 1976/4885ITGB2 4698/4885ICAM1 3533/4885 |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | SOS2 2246/4885ITGB2 4628/4885ICAM1 2383/4885 |
| US-20140378390-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | SOS2 2968/4885ITGB2 4513/4885ICAM1 2436/4885 |
| US-11008366-B2 | Peptidomimetic macrocycles | GLP1R, PROKR1, VIP | SOS2 2968/4885ITGB2 4513/4885ICAM1 2436/4885 |
| US-20220000968-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | SOS2 2246/4885ITGB2 4628/4885ICAM1 2383/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | SOS2 2891/4885ITGB2 4832/4885ICAM1 4009/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | SOS2 3369/4885ITGB2 1975/4885ICAM1 980/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | SOS2 2984/4885ITGB2 3941/4885ICAM1 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.